-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$26.6723.19% Upside
Capricor Therapeutics, Inc. Frequently Asked Questions
-
What analysts cover Capricor Therapeutics, Inc.?
Capricor Therapeutics, Inc. has been rated by research analysts at Maxim Group, H.C. Wainwright, Oppenheimer in the past 90 days.